<SEC-DOCUMENT>0001193125-22-301083.txt : 20221208
<SEC-HEADER>0001193125-22-301083.hdr.sgml : 20221208
<ACCEPTANCE-DATETIME>20221208164438
ACCESSION NUMBER:		0001193125-22-301083
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221208
FILED AS OF DATE:		20221208
DATE AS OF CHANGE:		20221208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		221452978

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d415743d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated December 8, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d415743dex991.htm">Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December 8, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d415743dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g415743g78m74.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Successfully Achieves Commercial Scale in Manufacturing of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eftilagimod Alpha </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>First
2,000L Manufacturing Run of its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> Soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> Protein </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Completed by WuXi Biologics </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY,
AUSTRALIA &#150; 8</B><B></B><B>&nbsp;December, 2022</B> &#150;<U> Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel
<FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces the successful <FONT STYLE="white-space:nowrap">scale-up</FONT> of the manufacturing of its lead product candidate eftilagimod alpha
(&#147;efti&#148; or &#147;IMP321&#148;), a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein, with the completion of a 2,000L manufacturing
run. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparation for late-stage clinical trials and commercial production, Immutep has been working with WuXi Biologics to increase the efti
manufacturing process from 200L to 2,000L capacity <FONT STYLE="white-space:nowrap">single-use</FONT> bioreactors at the manufacturing plant in Wuxi city, China. The first 2,000L manufacturing run has been performed successfully with all predefined
release criteria met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marc Voigt, CEO of Immutep said: </B>&#147;Following compelling results from the
<FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II trial and promising initial clinical data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> recently presented at SITC 2022, we are pleased to announce this significant achievement
reaching commercial scale in efti&#146;s manufacturing by WuXi Biologics, an important long-term partner of Immutep. With potential registrational trials in multiple indications for our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein, including our ongoing randomised <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Phase
IIb trial in 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> line head and neck cancer, this represents an important step towards potential commercial production of efti.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chris Chen, CEO of WuXi Biologics stated:</B> &#147;We are very pleased to be moving the scale up process forward for efti with Immutep. WuXi Biologics and
Immutep have been working together for many years and we are excited to continue supporting them as they advance towards potential commercialisation of efti.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to feedback from competent authorities, Immutep plans to introduce the material manufactured by the 2,000L scale process into ongoing and future Phase
II/III clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator for the treatment of cancer, capitalising on <FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> unique characteristics to stimulate both innate and
adaptive immunity. Efti binds to and activates antigen presenting cells via MHC II molecules leading to expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and monocytes. It also upregulates the
expression of key biological molecules like CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g415743g78m74.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid
tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and HER2&#150;/HR+ metastatic breast cancer. Its favourable safety profile enables various combinations,
including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States
Food and Drug Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About WuXi Biologics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organisation (CRDMO) offering <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-to-end</FONT></FONT> solutions that enable partners to discover, develop and manufacture biologics from concept to commercialisation for the benefit of patients worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to
provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology company leading the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy products for
the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT>
fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer in multiple
clinical trials. The Company is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> product candidates, including antibodies for immune
response modulation, are licensed to and being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the
Company&#146;s website <U>www.immutep.com</U> or by contacting: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim
McCarthy, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564; <U>tim@lifesciadvisors.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g415743g78m74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g415743g78m74.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M/(_9/P%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MI[8_#&*]4^M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * #I0ON _/33-1U _M"M;&^O#;CXC:G%Y!NIS"(UU2[ C\K?MV  #;C'
M%?,PE+^T[7=O;O2[M\3Z7L?EU&M6_P!:>3VL^3Z]47+S.UO:2LK7M9=CUO\
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M!)Q;WMLU?RZ'N<)9K7Q4:V!Q-1U9T(J=.4G>7)?EE&3>KY6XV;N]6GLCR_\
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M6ZIJ=[\5=9BO=1O[N)? >K2+%=7EQ<1K(NN^&5#A)9& <*S#(&<,1WH YO\
M;)'_ !>:0=/^*8T(>F/FO: .RM_V1/C9-!#-'X_\-JDL4<J*?$'BT%4=%95(
M70R,@$#@]J /M_Q+XIA^$'PG76M>9+ZX\+>&]*T]HH9G*ZKK4=K;:;;V\,TR
M"0QW&H;,RM'N6,O*R?(10!^<WAGPQ\7?VJ=?U;4]2\1"UT;39E%Q<7LEVF@Z
M7)<;GM]+T71K<E);@0C<WW6" //.9)$\T_0/T(?&7@7XJ_LN:UHVN:3XF\S3
MK^<I:ZCI4EU'IUU<6P$TNEZWI%P?+;?#N=4<S*Z*[1NKQ-Y9M\@V^1]U:Q\1
MG\9_LW:[\0-%FN-'U"[\$ZM<[K&XE@N-+UBQ2:TOH[6YB=98S#?6\PCD#*Q3
M8W!- 'YV_"GX5>,/CUJ6O)%XJC@ET."QN+RZ\076J7\TW]H2W21"':)6<J;6
M0L7=,;EQNR< '5^,?A;\9OV<6L_%6F>(V&E&ZBMSK'AJ_O/LL-P^3!:ZWI=Y
M#&C0S%6"B2.Y@8X1G#NJ$V#8_0#X _%M?BYX)75;N*"U\0Z/<#2_$%K!E83=
M+$LL%_;HQ)2UNH3O"DG9)'/&"1&&8V\K!MY6/<>GM^E&WD'Z!0 4 % !0 4
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MQ;* /E+X):?^TA<^%+R3X/WR6WAL:Y=+>QI<^$XG_ME;/3_/:1-:0W.?L9L
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !T]L?AC% #0$/0 X...<$'!Y]<BC;Y!:WR#Y2
M<<$KVX)'IQVZ46_ /T&[XHW6+?&LC LL990Y ZE4)R0/84;?(-O*P-Y:*SOM
M5%&YG8A54#DDL3P!ZYHV\K!MY#@5=05(9& *E3E2#R""#R,8YHV^0" (N2-H
MV\$Y VX'0GMP1U]:-OD&WR%(08X )Z=B<#/'X#]*-O(+6^0H*\@$?+P<$<8&
M<'TXQ1M\@V^0W$?&-O/W<$<\=B/:C;Y!;\!24QR5P#CJ, CH/KTXHL  *I(&
M 1@D# ('(''X'\J-OD&WR&B2)R\:O&S1X$B!E8IN&0'4'*Y'KCB@#*71O#PG
M\U=*T87.[/FK960G+@G)WB+=NSGOF@#7&Q1\NU5!VC&  0=NT8XSGC'KQ0 A
M>,'8716X 4LH8YZ?+G/- &<FDZ+#=_:(M-TR.^.7\]+.U2[.>K^:L8DZ]\T
M:>0N!D#LH)QDX)  ^@/Y4 5[F&SN(S;WD5O/%)\I@N4CDCDQT!BE!#]N,&@"
MK9Z1H^GLQT_3=-L7(^9K.SMK9R#TW&"-3@D'KZ4 >=?',C_A3GQ(VD$?\(CJ
MY!'(Q]F;&".U 'QU^PJB/JGQ(1U5D;3?#89& 92#<ZR""IX(QV- 'Z(VNG:?
M8[OL5C9V>\Y?[+;0V^\CH7\I%W'ZYH N4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MK<-%<:L95@:]MXA,R!T+!,[=ZYQD4;>0;>1]_4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 8H 3 XXZ<#VQ0
M8 XQ@#\.E "_T_3% !T]OTH 3 Z4 +C'X<?E0  8]OTH 3 ';&/PZ4 &!TQ_
MD4 +C_"@ QC\* #&/\^E "8'3&,?ATH ,#\OZ4 &!_GVH ,8H   .G'Z=* %
M_I^F* #'Z?I0 =/;]* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * .=_X2_PG_P!#/X?_ /!SIW;_
M +>:R]O1_P"?L%_V\O\ ,Y?KV!7_ #&4-/\ I[3_ /D@_P"$N\)_]#/X?_\
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M_P#\'.G?_)-'MJ/_ #]A_P"!+_,/K^!_Z#*'_@VG_P#)!_PEWA/_ *&?P_\
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M#Z_@?^@RA_X-I_\ R0?\)=X3_P"AG\/_ /@YT[_Y)H]M1_Y^P_\  E_F'U_
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M_P#0S^'_ /P<Z=_\DT>VH_\ /V'_ ($O\P^OX'_H,H?^#:?_ ,D'_"7>$_\
MH9_#_P#X.=._^2:/;4?^?L/_  )?YA]?P/\ T&4/_!M/_P"2#_A+O"?_ $,_
MA_\ \'.G?_)-'MJ/_/V'_@2_S#Z_@?\ H,H?^#:?_P D'_"7>$_^AG\/_P#@
MYT[_ .2:/;4?^?L/_ E_F'U_ _\ 090_\&T__D@_X2[PG_T,_A__ ,'.G?\
MR31[:C_S]A_X$O\ ,/K^!_Z#*'_@VG_\D'_"7>$_^AG\/_\ @YT[_P"2:/;4
M?^?L/_ E_F'U_ _]!E#_ ,&T_P#Y(/\ A+O"?_0S^'__  <Z=_\ )-'MJ/\
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MX-I__)!_PEWA/_H9_#__ (.=._\ DFCVU'_G[#_P)?YA]?P/_090_P#!M/\
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M?P__ .#G3O\ Y)H]M1_Y^P_\"7^8?7\#_P!!E#_P;3_^2#_A+O"?_0S^'_\
MP<Z=_P#)-'MJ/_/V'_@2_P P^OX'_H,H?^#:?_R0?\)=X3_Z&?P__P"#G3O_
M ))H]M1_Y^P_\"7^8?7\#_T&4/\ P;3_ /D@_P"$N\)_]#/X?_\ !SIW_P D
MT>VH_P#/V'_@2_S#Z_@?^@RA_P"#:?\ \D'_  EWA/\ Z&?P_P#^#G3O_DFC
MVU'_ )^P_P# E_F'U_ _]!E#_P &T_\ Y(/^$N\)_P#0S^'_ /P<Z=_\DT>V
MH_\ /V'_ ($O\P^OX'_H,H?^#:?_ ,D'_"7>$_\ H9_#_P#X.=._^2:/;4?^
M?L/_  )?YA]?P/\ T&4/_!M/_P"2#_A+O"?_ $,_A_\ \'.G?_)-'MJ/_/V'
M_@2_S#Z_@?\ H,H?^#:?_P D'_"7>$_^AG\/_P#@YT[_ .2:/;4?^?L/_ E_
MF'U_ _\ 090_\&T__D@_X2[PG_T,_A__ ,'.G?\ R31[:C_S]A_X$O\ ,/K^
M!_Z#*'_@VG_\D'_"7>$_^AG\/_\ @YT[_P"2:/;4?^?L/_ E_F'U_ _]!E#_
M ,&T_P#Y(/\ A+O"?_0S^'__  <Z=_\ )-'MJ/\ S]A_X$O\P^OX'_H,H?\
M@VG_ /)!_P )=X3_ .AG\/\ _@YT[_Y)H]M1_P"?L/\ P)?YA]?P/_090_\
M!M/_ .2#_A+O"?\ T,_A_P#\'.G?_)-'MJ/_ #]A_P"!+_,/K^!_Z#*'_@VG
M_P#)!_PEWA/_ *&?P_\ ^#G3O_DFCVU'_G[#_P "7^8?7\#_ -!E#_P;3_\
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M_P#\'.G?_)-'MJ/_ #]A_P"!+_,/K^!_Z#*'_@VG_P#)!_PEWA/_ *&?P_\
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M ,BT?5Y]X_C_ )!_9M?^:G]\O_D0_P"$,U3_ )[V'_?VX_\ D6CZO/O'\?\
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M^0?V;7_FI_?+_P"1#_A#-4_Y[V'_ ']N/_D6CZO/O'\?\@_LVO\ S4_OE_\
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M/[Y?_(A_PAFJ?\][#_O[<?\ R+1]7GWC^/\ D']FU_YJ?WR_^1#_ (0S5/\
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+O96Y6^GM?)=S_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
